Net loss was $39.0 million, or $0.75 loss per share, for the year ended December 31, 2024, compared to $35.6 million, or $0.68 loss per share, for the full year 2023. About GH Research PLC GH ...

27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq ... We are preparing to engage with the FDA in advance of providing a full response to the IND hold which we are on track to submit in mid ...

27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated ... We are preparing to engage with the FDA in advance of providing a full response to ...